Madrigal Pharmaceuticals (MDGL) Current Deferred Revenue (2010 - 2011)
Madrigal Pharmaceuticals (MDGL) posted quarterly Current Deferred Revenue of $3.3 million for Q3 2011, down 25.71% quarter-over-quarter from $4.4 million in Q2 2011.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Current Deferred Revenue (2010 - 2011) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Current Deferred Revenue for 2 consecutive years, with $3.3 million the latest figure, recorded in Q3 2011.
- In Q3 2011, Current Deferred Revenue changed N/A year-over-year to $3.3 million; the TTM figure through Sep 2011 stood at $3.3 million (changed N/A YoY), while the FY2010 annual figure was $4.6 million, changed N/A from the prior year.
- Current Deferred Revenue retreated to $3.3 million in Q3 2011 per MDGL's latest filing, from $4.4 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $4.6 million in Q4 2010 and bottomed at $3.3 million in Q3 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 15.81 Bn | 14.97 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2011 | 3.30 Mn |
| Jun 30, 2011 | 4.45 Mn |
| Dec 31, 2010 | 4.57 Mn |